Literature DB >> 18660854

Critical evaluation of urinary markers for bladder cancer detection and monitoring.

Shahrokh F Shariat, Jose A Karam, Yair Lotan, Pierre I Karakiewizc.   

Abstract

Bladder cancer is currently diagnosed using cystoscopy and cytology in patients with suspicious signs and symptoms. These tests are also used to monitor patients with a history of bladder cancer. The recurrence rate for bladder cancer is high, thus necessitating long-term follow-up. Urine cytology has high specificity but low sensitivity for low-grade bladder tumors. Recently, multiple noninvasive urine-based bladder cancer tests have been developed. Although several markers have been approved by the US Food and Drug Administration for bladder cancer surveillance, only a few are approved for detection of bladder cancer in high-risk patients.

Entities:  

Keywords:  Bladder cancer; Cystoscopy; Tumor markers; Urine cytology

Year:  2008        PMID: 18660854      PMCID: PMC2483317     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  119 in total

1.  Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer.

Authors:  H Leyh; M Marberger; P Conort; C Sternberg; V Pansadoro; F Pagano; P Bassi; L Boccon-Gibod; V Ravery; U Treiber; L Ishak
Journal:  Eur Urol       Date:  1999-01       Impact factor: 20.096

2.  Improved detection of recurrent bladder cancer using the Bard BTA stat Test.

Authors:  M F Sarosdy; M A Hudson; W J Ellis; M S Soloway; R deVere White; J Sheinfeld; M V Jarowenko; P F Schellhammer; E W Schervish; J V Patel; G W Chodak; D L Lamm; R D Johnson; M Henderson; G Adams; B A Blumenstein; K R Thoelke; R D Pfalzgraf; H A Murchison; S L Brunelle
Journal:  Urology       Date:  1997-09       Impact factor: 2.649

3.  Microsatellite analysis--DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial.

Authors:  B W van Rhijn; I Lurkin; W J Kirkels; T H van der Kwast; E C Zwarthoff
Journal:  Cancer       Date:  2001-08-15       Impact factor: 6.860

4.  Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis.

Authors:  J L Vriesema; M H Poucki; L A Kiemeney; J A Witjes
Journal:  Urology       Date:  2000-11-01       Impact factor: 2.649

5.  Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder.

Authors:  R Heicappell; M Schostak; M Müller; K Miller
Journal:  Scand J Clin Lab Invest       Date:  2000-07       Impact factor: 1.713

Review 6.  HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade.

Authors:  V B Lokeshwar; N L Block
Journal:  Urol Clin North Am       Date:  2000-02       Impact factor: 2.241

7.  Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes.

Authors:  D H Lee; S C Yang; S J Hong; B H Chung; I Y Kim
Journal:  Clin Cancer Res       Date:  1998-03       Impact factor: 12.531

8.  Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy.

Authors:  Jörg Schmidbauer; Fred Witjes; Nikolaus Schmeller; Roland Donat; Martin Susani; Michael Marberger
Journal:  J Urol       Date:  2004-01       Impact factor: 7.450

9.  Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder.

Authors:  Pierre I Karakiewicz; Serge Benayoun; Craig Zippe; Gerson Lüdecke; Hans Boman; Marta Sanchez-Carbayo; Roberto Casella; Christine Mian; Martin G Friedrich; Sanaa Eissa; Hideyuki Akaza; Hartwig Huland; Hans Hedelin; Raina Rupesh; Naoto Miyanaga; Arthur I Sagalowsky; Michael J Marberger; Shahrokh F Shariat
Journal:  BJU Int       Date:  2006-03-17       Impact factor: 5.588

10.  [Usefulness of BTA Stat test (Bard) in the diagnosis of bladder cancer. Preliminary results and comparison with cytology and cystoscopy].

Authors:  J L Gutiérrez Baños; B Martín García; R Hernández Rodríguez; J A Portillo Martín; M A Correas Gómez; J I del Valle Schaan; A Roca Edreira; A Villanueva Peña; R Gutíerrez García; E De Diego Rodríguez; M A Rado Velázquez
Journal:  Arch Esp Urol       Date:  1998-10       Impact factor: 0.436

View more
  29 in total

Review 1.  Immunological basis in the pathogenesis and treatment of bladder cancer.

Authors:  David B Thompson; Larry E Siref; Michael P Feloney; Ralph J Hauke; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2014-11-13       Impact factor: 4.473

2.  Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines.

Authors:  Beate Pesch; Dirk Taeger; Georg Johnen; Katarzyna Gawrych; Nadine Bonberg; Christian Schwentner; Harald Wellhäusser; Matthias Kluckert; Gabriele Leng; Michael Nasterlack; Yair Lotan; Arnulf Stenzl; Thomas Brüning
Journal:  Int Arch Occup Environ Health       Date:  2013-10-16       Impact factor: 3.015

3.  Bladder Cancer Academy 2018 Selected Summaries.

Authors:  Nermarie Velázquez
Journal:  Rev Urol       Date:  2018

4.  Developing urinary metabolomic signatures as early bladder cancer diagnostic markers.

Authors:  Chong Shen; Zeyu Sun; Deying Chen; Xiaoling Su; Jing Jiang; Gonghui Li; Biaoyang Lin; Jiajun Yan
Journal:  OMICS       Date:  2015-01

5.  Influence of age on false positive rates of urine-based tumor markers.

Authors:  M Horstmann; T Todenhöfer; J Hennenlotter; S Aufderklamm; J Mischinger; U Kuehs; G Gakis; A Stenzl; C Schwentner
Journal:  World J Urol       Date:  2012-07-18       Impact factor: 4.226

6.  Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Authors:  Andrew J Vickers; Caroline Bennette; Adam S Kibel; Amanda Black; Grant Izmirlian; Andrew J Stephenson; Bernard Bochner
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

7.  Individual risk assessment in bladder cancer patients based on a multi-marker panel.

Authors:  Tilman Todenhöfer; Jörg Hennenlotter; Stefan Aufderklamm; Ursula Kühs; Georgios Gakis; Miriam Germann; Arnulf Stenzl; Christian Schwentner
Journal:  J Cancer Res Clin Oncol       Date:  2012-08-15       Impact factor: 4.553

8.  Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I study.

Authors:  Huyen T Nguyen; Zarine K Shah; Amir Mortazavi; Kamal S Pohar; Lai Wei; Guang Jia; Debra L Zynger; Michael V Knopp
Journal:  Eur Radiol       Date:  2016-08-23       Impact factor: 5.315

9.  ROS generation via NOX4 and its utility in the cytological diagnosis of urothelial carcinoma of the urinary bladder.

Authors:  Keiji Shimada; Tomomi Fujii; Satoshi Anai; Kiyohide Fujimoto; Noboru Konishi
Journal:  BMC Urol       Date:  2011-10-28       Impact factor: 2.264

10.  Point-of-Care Tests for Bladder Cancer: The Influencing Role of Hematuria.

Authors:  Joerg Hennenlotter; Severine Huber; Tilman Todenhöfer; Ursula Kuehs; David Schilling; Stefan Aufderklamm; Georgios Gakis; Christian Schwentner; Arnulf Stenzl
Journal:  Adv Urol       Date:  2011-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.